A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world

BACKGROUND: Anlotinib is a new multi-target tyrosine kinase inhibitor (TKI) and has been shown to have antitumor effects and synergistic antitumor effects with immunotherapy only in animal studies and in the 2nd-line treatment in small clinical trials. A real-world study with large sample to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yue, Ji, Min, Jiang, Yingying, Yin, Rong, Wang, Zihan, Li, Hang, Wang, Shuaiyu, He, Kang, Ma, Yuxin, Wang, Zhitong, Lu, Jianwei, Shi, Meiqi, Shen, Bo, Zhou, Guoren, Leong, Tracy L., Wang, Xiaohua, Chen, Cheng, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271442/
https://www.ncbi.nlm.nih.gov/pubmed/35832459
http://dx.doi.org/10.21037/tlcr-22-350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271442/
https://www.ncbi.nlm.nih.gov/pubmed/35832459
http://dx.doi.org/10.21037/tlcr-22-350

Ejemplares similares